Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05575505 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Final enrollment: 60 participants (planned 44) · Primary completion date changed from estimate of Feb 2026 to May 20, 2025 · Eligibility criteria expanded, about 10 words · 1 more Show 4 more changesShow less
    • Final enrollment: 60 participants (planned 44)
    • Primary completion date changed from estimate of Feb 2026 to May 20, 2025
    • Eligibility criteria expanded, about 10 words
    • Site details revised
  2. Primary completion date: Feb 2025 to Feb 2026v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Feb 2023 to Feb 2, 2023v3 Show 1 more changeShow less
    • Start date changed from estimate of Feb 2023 to Feb 2, 2023
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Also, it is associated with high risk of colon cancer, so there is a continuous need for introducing new therapies that decrease progression, and hence better outcomes
Trial Details
NCT Number NCT05575505
Lead Sponsor Tanta University
Conditions Inflammatory Bowel Diseases
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov